Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts

G. M. Kolfschoten, T. M. Hulscher, H. M. Pinedo, E. Boven

Research output: Contribution to journalArticle

Abstract

Multidrug resistance (MDR and more specifically the expression of P-glycoprotein (Pgp) have been studied extensively in vitro. Unfortunately, it appears that the predictive value of MDR recognized in vitro is mostly an incorrect measure to determine the responsiveness of a particular tumour in the clinic. This misunderstood or overvalued role of MDR might explain the failure of strategies to reverse Pgp function by the use of modulators in solid tumours. To obtain more insight in in vivo drug resistance we investigated a panel of 15 human ovarian cancer xenografts consisting of the most common histological subtypes known in ovarian cancer patients. The response rate to cisplatin, cyclophosphamide and doxorubicin in the xenografts resembled the results of phase II trials with these agents in ovarian cancer patients. This resemblance justifies drug resistance studies in this experimental in vivo human tumour system. We determined the expression levels of MDR1, MRP1, LRP and topoisomerase IIα mRNA by the RNase protection assay and the presence of MRP1 and LRP proteins by immunohistochemistry. The S-phase fraction was investigated as a separate parameter by flow cytometry. In none of the 15 ovarian cancer xenografts was MDR1 expression detectable. The expression levels of MRP1 and LRP were low to moderate and resembled the presence of the MRP1 and LRP proteins. There was a weak, inverse relationship between the expression levels of LRP and sensitivity to cisplatin and cyclophosphamide (r = -0.44 and -0.45), but not to doxorubicin. The levels of topoisomerase IIα varied among the xenografts (0.73-2.66) and failed to correlate with doxorubicin resistance (r = 0.14). The S-phase fraction, however, showed a relation with the sensitivity to cisplatin (r = 0.66). Among the determinants studied in ovarian cancer in vivo, LRP mRNA and the S-phase fraction were the best predictive factors for drug response and most specifically for the activity of cisplatin. (C) 2000 Cancer Research Campaign.

Original languageEnglish (US)
Pages (from-to)921-927
Number of pages7
JournalBritish Journal of Cancer
Volume83
Issue number7
StatePublished - 2000
Externally publishedYes

Fingerprint

S Phase
Drug Resistance
Heterografts
Ovarian Neoplasms
Cisplatin
Doxorubicin
Type II DNA Topoisomerase
Pharmaceutical Preparations
P-Glycoprotein
Cyclophosphamide
Neoplasms
Messenger RNA
Multiple Drug Resistance
Ribonucleases
Flow Cytometry
Proteins
Immunohistochemistry
In Vitro Techniques

Keywords

  • Drug resistance
  • LRP
  • Ovarian cancer xenografts
  • S-phase fraction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. / Kolfschoten, G. M.; Hulscher, T. M.; Pinedo, H. M.; Boven, E.

In: British Journal of Cancer, Vol. 83, No. 7, 2000, p. 921-927.

Research output: Contribution to journalArticle

Kolfschoten, G. M. ; Hulscher, T. M. ; Pinedo, H. M. ; Boven, E. / Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. In: British Journal of Cancer. 2000 ; Vol. 83, No. 7. pp. 921-927.
@article{a84f80dd8c8d4500b77de4adfa348b41,
title = "Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts",
abstract = "Multidrug resistance (MDR and more specifically the expression of P-glycoprotein (Pgp) have been studied extensively in vitro. Unfortunately, it appears that the predictive value of MDR recognized in vitro is mostly an incorrect measure to determine the responsiveness of a particular tumour in the clinic. This misunderstood or overvalued role of MDR might explain the failure of strategies to reverse Pgp function by the use of modulators in solid tumours. To obtain more insight in in vivo drug resistance we investigated a panel of 15 human ovarian cancer xenografts consisting of the most common histological subtypes known in ovarian cancer patients. The response rate to cisplatin, cyclophosphamide and doxorubicin in the xenografts resembled the results of phase II trials with these agents in ovarian cancer patients. This resemblance justifies drug resistance studies in this experimental in vivo human tumour system. We determined the expression levels of MDR1, MRP1, LRP and topoisomerase IIα mRNA by the RNase protection assay and the presence of MRP1 and LRP proteins by immunohistochemistry. The S-phase fraction was investigated as a separate parameter by flow cytometry. In none of the 15 ovarian cancer xenografts was MDR1 expression detectable. The expression levels of MRP1 and LRP were low to moderate and resembled the presence of the MRP1 and LRP proteins. There was a weak, inverse relationship between the expression levels of LRP and sensitivity to cisplatin and cyclophosphamide (r = -0.44 and -0.45), but not to doxorubicin. The levels of topoisomerase IIα varied among the xenografts (0.73-2.66) and failed to correlate with doxorubicin resistance (r = 0.14). The S-phase fraction, however, showed a relation with the sensitivity to cisplatin (r = 0.66). Among the determinants studied in ovarian cancer in vivo, LRP mRNA and the S-phase fraction were the best predictive factors for drug response and most specifically for the activity of cisplatin. (C) 2000 Cancer Research Campaign.",
keywords = "Drug resistance, LRP, Ovarian cancer xenografts, S-phase fraction",
author = "Kolfschoten, {G. M.} and Hulscher, {T. M.} and Pinedo, {H. M.} and E. Boven",
year = "2000",
language = "English (US)",
volume = "83",
pages = "921--927",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts

AU - Kolfschoten, G. M.

AU - Hulscher, T. M.

AU - Pinedo, H. M.

AU - Boven, E.

PY - 2000

Y1 - 2000

N2 - Multidrug resistance (MDR and more specifically the expression of P-glycoprotein (Pgp) have been studied extensively in vitro. Unfortunately, it appears that the predictive value of MDR recognized in vitro is mostly an incorrect measure to determine the responsiveness of a particular tumour in the clinic. This misunderstood or overvalued role of MDR might explain the failure of strategies to reverse Pgp function by the use of modulators in solid tumours. To obtain more insight in in vivo drug resistance we investigated a panel of 15 human ovarian cancer xenografts consisting of the most common histological subtypes known in ovarian cancer patients. The response rate to cisplatin, cyclophosphamide and doxorubicin in the xenografts resembled the results of phase II trials with these agents in ovarian cancer patients. This resemblance justifies drug resistance studies in this experimental in vivo human tumour system. We determined the expression levels of MDR1, MRP1, LRP and topoisomerase IIα mRNA by the RNase protection assay and the presence of MRP1 and LRP proteins by immunohistochemistry. The S-phase fraction was investigated as a separate parameter by flow cytometry. In none of the 15 ovarian cancer xenografts was MDR1 expression detectable. The expression levels of MRP1 and LRP were low to moderate and resembled the presence of the MRP1 and LRP proteins. There was a weak, inverse relationship between the expression levels of LRP and sensitivity to cisplatin and cyclophosphamide (r = -0.44 and -0.45), but not to doxorubicin. The levels of topoisomerase IIα varied among the xenografts (0.73-2.66) and failed to correlate with doxorubicin resistance (r = 0.14). The S-phase fraction, however, showed a relation with the sensitivity to cisplatin (r = 0.66). Among the determinants studied in ovarian cancer in vivo, LRP mRNA and the S-phase fraction were the best predictive factors for drug response and most specifically for the activity of cisplatin. (C) 2000 Cancer Research Campaign.

AB - Multidrug resistance (MDR and more specifically the expression of P-glycoprotein (Pgp) have been studied extensively in vitro. Unfortunately, it appears that the predictive value of MDR recognized in vitro is mostly an incorrect measure to determine the responsiveness of a particular tumour in the clinic. This misunderstood or overvalued role of MDR might explain the failure of strategies to reverse Pgp function by the use of modulators in solid tumours. To obtain more insight in in vivo drug resistance we investigated a panel of 15 human ovarian cancer xenografts consisting of the most common histological subtypes known in ovarian cancer patients. The response rate to cisplatin, cyclophosphamide and doxorubicin in the xenografts resembled the results of phase II trials with these agents in ovarian cancer patients. This resemblance justifies drug resistance studies in this experimental in vivo human tumour system. We determined the expression levels of MDR1, MRP1, LRP and topoisomerase IIα mRNA by the RNase protection assay and the presence of MRP1 and LRP proteins by immunohistochemistry. The S-phase fraction was investigated as a separate parameter by flow cytometry. In none of the 15 ovarian cancer xenografts was MDR1 expression detectable. The expression levels of MRP1 and LRP were low to moderate and resembled the presence of the MRP1 and LRP proteins. There was a weak, inverse relationship between the expression levels of LRP and sensitivity to cisplatin and cyclophosphamide (r = -0.44 and -0.45), but not to doxorubicin. The levels of topoisomerase IIα varied among the xenografts (0.73-2.66) and failed to correlate with doxorubicin resistance (r = 0.14). The S-phase fraction, however, showed a relation with the sensitivity to cisplatin (r = 0.66). Among the determinants studied in ovarian cancer in vivo, LRP mRNA and the S-phase fraction were the best predictive factors for drug response and most specifically for the activity of cisplatin. (C) 2000 Cancer Research Campaign.

KW - Drug resistance

KW - LRP

KW - Ovarian cancer xenografts

KW - S-phase fraction

UR - http://www.scopus.com/inward/record.url?scp=0033830420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033830420&partnerID=8YFLogxK

M3 - Article

C2 - 10970695

AN - SCOPUS:0033830420

VL - 83

SP - 921

EP - 927

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -